

Table 1.17

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Both Sexes, Total U.S., 2015-2017

| Site | All Races | Whites | Blacks |
|----------------------------------|------------------------|------------------------|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 19.37 (19.34, 19.40) | 19.52 (19.49, 19.55) | 19.26 (19.17, 19.34) |
| Oral Cavity and Pharynx | 0.30 (0.30, 0.31) | 0.31 (0.30, 0.31) | 0.26 (0.25, 0.27) |
| Esophagus | 0.46 (0.46, 0.47) | 0.49 (0.49, 0.50) | 0.31 (0.30, 0.32) |
| Stomach | 0.36 (0.36, 0.36) | 0.31 (0.31, 0.32) | 0.57 (0.56, 0.59) |
| Colon and Rectum | 1.72 (1.71, 1.73) | 1.69 (1.68, 1.70) | 1.99 (1.96, 2.02) |
| Liver and Intrahepatic Bile Duct | 0.78 (0.77, 0.79) | 0.74 (0.73, 0.75) | 0.87 (0.85, 0.89) |
| Pancreas | 1.38 (1.37, 1.39) | 1.38 (1.37, 1.38) | 1.45 (1.42, 1.47) |
| Larynx | 0.11 (0.11, 0.11) | 0.11 (0.11, 0.11) | 0.16 (0.15, 0.17) |
| Lung and Bronchus | 4.76 (4.74, 4.77) | 4.87 (4.86, 4.89) | 4.30 (4.26, 4.34) |
| Melanoma of the Skin | 0.27 (0.26, 0.27) | 0.31 (0.31, 0.31) | 0.03 (0.03, 0.04) |
| Breast | 1.32 (1.31, 1.33) | 1.29 (1.28, 1.30) | 1.65 (1.62, 1.68) |
| Urinary Bladder | 0.62 (0.61, 0.62) | 0.65 (0.64, 0.65) | 0.42 (0.41, 0.44) |
| Kidney and Renal Pelvis | 0.45 (0.45, 0.46) | 0.47 (0.46, 0.47) | 0.38 (0.37, 0.39) |
| Brain and Other Nervous System | 0.47 (0.47, 0.48) | 0.52 (0.51, 0.52) | 0.25 (0.24, 0.26) |
| Thyroid | 0.06 (0.06, 0.07) | 0.06 (0.06, 0.07) | 0.05 (0.05, 0.06) |
| Hodgkin Lymphoma | 0.03 (0.03, 0.03) | 0.03 (0.03, 0.04) | 0.02 (0.02, 0.03) |
| Non-Hodgkin Lymphoma | 0.70 (0.70, 0.71) | 0.74 (0.73, 0.75) | 0.42 (0.40, 0.43) |
| Myeloma | 0.42 (0.41, 0.42) | 0.39 (0.39, 0.39) | 0.67 (0.65, 0.69) |
| Leukemia | 0.80 (0.79, 0.81) | 0.84 (0.83, 0.84) | 0.57 (0.56, 0.59) |
| Acute Lymphocytic Leukemia | 0.04 (0.04, 0.04) | 0.05 (0.04, 0.05) | 0.03 (0.02, 0.03) |
| Chronic Lymphocytic Leukemia | 0.17 (0.16, 0.17) | 0.18 (0.17, 0.18) | 0.12 (0.11, 0.12) |
| Acute Myeloid Leukemia | 0.33 (0.33, 0.34) | 0.35 (0.35, 0.35) | 0.23 (0.22, 0.24) |
| Chronic Myeloid Leukemia | 0.04 (0.04, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.03, 0.04) |

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2015-2017

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 17.66 (17.47, 17.86) | 15.72 (15.31, 16.15) | 16.95 (16.83, 17.07) |
| Oral Cavity and Pharynx | 0.33 (0.30, 0.36) | 0.24 (0.19, 0.32) | 0.23 (0.22, 0.25) |
| Esophagus | 0.26 (0.23, 0.28) | 0.36 (0.30, 0.44) | 0.29 (0.27, 0.31) |
| Stomach | 0.96 (0.91, 1.01) | 0.46 (0.40, 0.56) | 0.71 (0.69, 0.74) |
| Colon and Rectum | 1.77 (1.70, 1.84) | 1.72 (1.58, 1.89) | 1.72 (1.68, 1.77) |
| Liver and Intrahepatic Bile Duct | 1.43 (1.38, 1.49) | 1.13 (1.02, 1.25) | 1.31 (1.28, 1.35) |
| Pancreas | 1.41 (1.35, 1.47) | 1.03 (0.91, 1.17) | 1.31 (1.28, 1.35) |
| Larynx | 0.06 (0.05, 0.07) | 0.09 (0.06, 0.14) | 0.10 (0.09, 0.11) |
| Lung and Bronchus | 3.95 (3.85, 4.04) | 3.51 (3.32, 3.73) | 2.64 (2.59, 2.69) |
| Melanoma of the Skin | 0.06 (0.05, 0.08) | 0.07 (0.05, 0.13) | 0.10 (0.09, 0.11) |
| Breast | 0.99 (0.94, 1.04) | 0.97 (0.85, 1.11) | 1.08 (1.05, 1.12) |
| Urinary Bladder | 0.44 (0.40, 0.48) | 0.37 (0.29, 0.47) | 0.46 (0.43, 0.48) |
| Kidney and Renal Pelvis | 0.31 (0.28, 0.34) | 0.58 (0.50, 0.69) | 0.52 (0.49, 0.54) |
| Brain and Other Nervous System | 0.32 (0.29, 0.34) | 0.25 (0.20, 0.33) | 0.38 (0.37, 0.40) |
| Thyroid | 0.12 (0.10, 0.14) | 0.06 (0.03, 0.13) | 0.11 (0.10, 0.12) |
| Hodgkin Lymphoma | 0.02 (0.02, 0.03) | 0.04 (0.02, 0.09) | 0.05 (0.05, 0.06) |
| Non-Hodgkin Lymphoma | 0.69 (0.65, 0.73) | 0.47 (0.40, 0.57) | 0.72 (0.69, 0.74) |
| Myeloma | 0.29 (0.26, 0.32) | 0.35 (0.28, 0.44) | 0.41 (0.39, 0.43) |
| Leukemia | 0.60 (0.57, 0.64) | 0.42 (0.35, 0.51) | 0.65 (0.63, 0.68) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.06) | 0.04 (0.03, 0.10) | 0.07 (0.06, 0.08) |
| Chronic Lymphocytic Leukemia | 0.05 (0.04, 0.06) | 0.03 (0.02, 0.09) | 0.09 (0.08, 0.10) |
| Acute Myeloid Leukemia | 0.32 (0.30, 0.35) | 0.17 (0.13, 0.24) | 0.26 (0.25, 0.28) |
| Chronic Myeloid Leukemia | 0.03 (0.02, 0.04) | 0.02 (0.01, 0.07) | 0.04 (0.03, 0.05) |

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2015-2017

| Site | All Races | | Whites | | Blacks | |
|----------------------------------|-----------|------------------|---------|------------------|---------|------------------|
| | Percent | (95% C.I.) | Percent | (95% C.I.) | Percent | (95% C.I.) |
| All Sites | 20.89 | (20.85, 20.93) | 21.02 | (20.98, 21.06) | 20.80 | (20.67, 20.93) |
| Oral Cavity and Pharynx | 0.42 | (0.41, 0.43) | 0.42 | (0.42, 0.43) | 0.38 | (0.37, 0.40) |
| Esophagus | 0.74 | (0.74, 0.75) | 0.80 | (0.79, 0.81) | 0.46 | (0.44, 0.48) |
| Stomach | 0.43 | (0.43, 0.44) | 0.38 | (0.37, 0.38) | 0.71 | (0.68, 0.74) |
| Colon and Rectum | 1.80 | (1.78, 1.81) | 1.76 | (1.75, 1.77) | 2.10 | (2.06, 2.15) |
| Liver and Intrahepatic Bile Duct | 1.03 | (1.02, 1.04) | 0.97 | (0.96, 0.98) | 1.21 | (1.18, 1.24) |
| Pancreas | 1.40 | (1.39, 1.41) | 1.41 | (1.40, 1.43) | 1.36 | (1.33, 1.40) |
| Larynx | 0.18 | (0.18, 0.19) | 0.18 | (0.17, 0.18) | 0.27 | (0.26, 0.29) |
| Lung and Bronchus | 5.22 | (5.20, 5.24) | 5.27 | (5.25, 5.29) | 5.12 | (5.05, 5.18) |
| Melanoma of the Skin | 0.36 | (0.36, 0.37) | 0.42 | (0.41, 0.42) | 0.03 | (0.03, 0.04) |
| Breast | 0.03 | (0.03, 0.03) | 0.03 | (0.03, 0.03) | 0.05 | (0.04, 0.05) |
| Prostate | 2.43 | (2.41, 2.44) | 2.28 | (2.26, 2.30) | 3.87 | (3.80, 3.94) |
| Testis | 0.02 | (0.02, 0.02) | 0.02 | (0.02, 0.02) | 0.01 | (0.01, 0.01) |
| Urinary Bladder | 0.93 | (0.92, 0.94) | 0.98 | (0.97, 0.99) | 0.53 | (0.50, 0.56) |
| Kidney and Renal Pelvis | 0.59 | (0.58, 0.59) | 0.61 | (0.60, 0.61) | 0.49 | (0.47, 0.51) |
| Brain and Other Nervous System | 0.53 | (0.52, 0.54) | 0.58 | (0.57, 0.58) | 0.27 | (0.26, 0.29) |
| Thyroid | 0.06 | (0.06, 0.06) | 0.06 | (0.06, 0.06) | 0.04 | (0.03, 0.04) |
| Hodgkin Lymphoma | 0.04 | (0.04, 0.04) | 0.04 | (0.04, 0.04) | 0.03 | (0.02, 0.03) |
| Non-Hodgkin Lymphoma | 0.80 | (0.79, 0.81) | 0.84 | (0.83, 0.85) | 0.46 | (0.44, 0.48) |
| Myeloma | 0.47 | (0.46, 0.47) | 0.44 | (0.44, 0.45) | 0.69 | (0.67, 0.72) |
| Leukemia | 0.94 | (0.93, 0.95) | 0.99 | (0.98, 1.00) | 0.62 | (0.60, 0.65) |
| Acute Lymphocytic Leukemia | 0.05 | (0.05, 0.05) | 0.05 | (0.05, 0.05) | 0.03 | (0.02, 0.03) |
| Chronic Lymphocytic Leukemia | 0.20 | (0.20, 0.21) | 0.22 | (0.21, 0.22) | 0.14 | (0.13, 0.15) |
| Acute Myeloid Leukemia | 0.39 | (0.38, 0.40) | 0.41 | (0.40, 0.42) | 0.24 | (0.22, 0.25) |
| Chronic Myeloid Leukemia | 0.05 | (0.04, 0.05) | 0.05 | (0.04, 0.05) | 0.03 | (0.03, 0.04) |

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Males, Total U.S., 2015-2017

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 20.00 (19.69, 20.31) | 16.22 (15.64, 16.86) | 19.02 (18.83, 19.21) |
| Oral Cavity and Pharynx | 0.45 (0.41, 0.50) | 0.31 (0.24, 0.46) | 0.33 (0.31, 0.36) |
| Esophagus | 0.41 (0.37, 0.46) | 0.56 (0.46, 0.74) | 0.48 (0.45, 0.51) |
| Stomach | 1.12 (1.05, 1.21) | 0.53 (0.43, 0.71) | 0.82 (0.78, 0.86) |
| Colon and Rectum | 1.84 (1.74, 1.95) | 1.76 (1.57, 2.02) | 1.96 (1.89, 2.03) |
| Liver and Intrahepatic Bile Duct | 1.93 (1.85, 2.02) | 1.37 (1.21, 1.59) | 1.66 (1.61, 1.71) |
| Pancreas | 1.39 (1.31, 1.48) | 0.98 (0.84, 1.19) | 1.27 (1.22, 1.32) |
| Larynx | 0.10 (0.08, 0.12) | 0.15 (0.10, 0.29) | 0.19 (0.17, 0.22) |
| Lung and Bronchus | 4.90 (4.74, 5.06) | 3.63 (3.34, 3.97) | 3.27 (3.19, 3.36) |
| Melanoma of the Skin | 0.06 (0.04, 0.10) | 0.09 (0.05, 0.23) | 0.12 (0.10, 0.14) |
| Breast | 0.03 (0.01, 0.06) | 0.00 (0.00, 0.15) | 0.02 (0.02, 0.03) |
| Prostate | 2.21 (2.07, 2.36) | 2.04 (1.77, 2.39) | 2.80 (2.70, 2.90) |
| Testis | 0.01 (0.00, 0.02) | 0.02 (0.01, 0.17) | 0.02 (0.02, 0.03) |
| Urinary Bladder | 0.70 (0.62, 0.78) | 0.50 (0.39, 0.70) | 0.69 (0.64, 0.74) |
| Kidney and Renal Pelvis | 0.44 (0.39, 0.50) | 0.72 (0.61, 0.92) | 0.68 (0.64, 0.72) |
| Brain and Other Nervous System | 0.35 (0.31, 0.39) | 0.25 (0.18, 0.41) | 0.41 (0.39, 0.44) |
| Thyroid | 0.10 (0.08, 0.14) | 0.05 (0.02, 0.19) | 0.09 (0.08, 0.11) |
| Hodgkin Lymphoma | 0.02 (0.02, 0.05) | 0.03 (0.01, 0.18) | 0.05 (0.04, 0.07) |
| Non-Hodgkin Lymphoma | 0.83 (0.76, 0.90) | 0.53 (0.43, 0.72) | 0.80 (0.76, 0.85) |
| Myeloma | 0.34 (0.30, 0.39) | 0.37 (0.26, 0.56) | 0.46 (0.43, 0.49) |
| Leukemia | 0.75 (0.70, 0.82) | 0.52 (0.40, 0.72) | 0.77 (0.72, 0.81) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.06) | 0.05 (0.03, 0.19) | 0.07 (0.06, 0.08) |
| Chronic Lymphocytic Leukemia | 0.07 (0.05, 0.10) | 0.04 (0.02, 0.19) | 0.11 (0.09, 0.14) |
| Acute Myeloid Leukemia | 0.40 (0.36, 0.45) | 0.18 (0.12, 0.33) | 0.30 (0.28, 0.33) |
| Chronic Myeloid Leukemia | 0.04 (0.02, 0.06) | 0.03 (0.01, 0.18) | 0.06 (0.04, 0.08) |

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2015-2017

| Site | All Races | Whites | Blacks |
|----------------------------------|------------------------|------------------------|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 18.11 (18.07, 18.14) | 18.26 (18.22, 18.30) | 18.17 (18.05, 18.28) |
| Oral Cavity and Pharynx | 0.19 (0.18, 0.19) | 0.19 (0.19, 0.20) | 0.15 (0.14, 0.16) |
| Esophagus | 0.20 (0.19, 0.20) | 0.20 (0.20, 0.21) | 0.18 (0.17, 0.20) |
| Stomach | 0.29 (0.29, 0.30) | 0.25 (0.25, 0.26) | 0.46 (0.44, 0.48) |
| Colon and Rectum | 1.65 (1.64, 1.66) | 1.62 (1.60, 1.63) | 1.90 (1.86, 1.95) |
| Liver and Intrahepatic Bile Duct | 0.54 (0.54, 0.55) | 0.52 (0.51, 0.53) | 0.57 (0.55, 0.60) |
| Pancreas | 1.36 (1.35, 1.37) | 1.34 (1.33, 1.35) | 1.52 (1.49, 1.56) |
| Larynx | 0.05 (0.04, 0.05) | 0.05 (0.04, 0.05) | 0.07 (0.06, 0.07) |
| Lung and Bronchus | 4.34 (4.32, 4.36) | 4.51 (4.49, 4.53) | 3.61 (3.56, 3.66) |
| Melanoma of the Skin | 0.18 (0.18, 0.19) | 0.21 (0.20, 0.21) | 0.03 (0.03, 0.04) |
| Breast | 2.54 (2.53, 2.56) | 2.51 (2.49, 2.52) | 3.05 (3.00, 3.10) |
| Cervix Uteri | 0.22 (0.22, 0.22) | 0.21 (0.20, 0.21) | 0.32 (0.31, 0.34) |
| Corpus and Uterus, NOS | 0.64 (0.63, 0.65) | 0.60 (0.59, 0.60) | 1.02 (0.99, 1.04) |
| Ovary | 0.86 (0.85, 0.87) | 0.90 (0.89, 0.91) | 0.68 (0.66, 0.70) |
| Urinary Bladder | 0.35 (0.34, 0.35) | 0.35 (0.35, 0.36) | 0.34 (0.32, 0.36) |
| Kidney and Renal Pelvis | 0.32 (0.32, 0.33) | 0.33 (0.33, 0.34) | 0.29 (0.27, 0.30) |
| Brain and Other Nervous System | 0.42 (0.41, 0.43) | 0.46 (0.45, 0.47) | 0.23 (0.22, 0.25) |
| Thyroid | 0.07 (0.07, 0.07) | 0.07 (0.07, 0.07) | 0.07 (0.06, 0.08) |
| Hodgkin Lymphoma | 0.03 (0.03, 0.03) | 0.03 (0.03, 0.03) | 0.02 (0.02, 0.02) |
| Non-Hodgkin Lymphoma | 0.62 (0.61, 0.63) | 0.65 (0.64, 0.66) | 0.38 (0.36, 0.40) |
| Myeloma | 0.37 (0.37, 0.38) | 0.34 (0.33, 0.35) | 0.66 (0.63, 0.68) |
| Leukemia | 0.67 (0.66, 0.68) | 0.70 (0.69, 0.71) | 0.53 (0.51, 0.56) |
| Acute Lymphocytic Leukemia | 0.04 (0.04, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.02, 0.03) |
| Chronic Lymphocytic Leukemia | 0.14 (0.13, 0.14) | 0.14 (0.14, 0.15) | 0.10 (0.09, 0.11) |
| Acute Myeloid Leukemia | 0.28 (0.28, 0.29) | 0.29 (0.29, 0.30) | 0.22 (0.21, 0.23) |
| Chronic Myeloid Leukemia | 0.03 (0.03, 0.04) | 0.04 (0.03, 0.04) | 0.03 (0.02, 0.04) |

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2015-2017

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 15.90 (15.66, 16.15) | 15.27 (14.69, 15.89) | 15.42 (15.27, 15.58) |
| Oral Cavity and Pharynx | 0.22 (0.19, 0.26) | 0.17 (0.10, 0.30) | 0.15 (0.13, 0.17) |
| Esophagus | 0.13 (0.11, 0.16) | 0.16 (0.11, 0.27) | 0.13 (0.11, 0.14) |
| Stomach | 0.82 (0.76, 0.89) | 0.40 (0.31, 0.54) | 0.63 (0.59, 0.66) |
| Colon and Rectum | 1.71 (1.62, 1.80) | 1.67 (1.46, 1.93) | 1.53 (1.48, 1.59) |
| Liver and Intrahepatic Bile Duct | 1.02 (0.96, 1.09) | 0.89 (0.75, 1.07) | 1.00 (0.96, 1.04) |
| Pancreas | 1.42 (1.35, 1.50) | 1.06 (0.89, 1.28) | 1.35 (1.30, 1.40) |
| Larynx | 0.02 (0.01, 0.04) | 0.02 (0.01, 0.12) | 0.02 (0.02, 0.03) |
| Lung and Bronchus | 3.19 (3.08, 3.31) | 3.41 (3.14, 3.73) | 2.12 (2.06, 2.18) |
| Melanoma of the Skin | 0.05 (0.04, 0.08) | 0.06 (0.03, 0.16) | 0.08 (0.07, 0.10) |
| Breast | 1.78 (1.70, 1.86) | 1.90 (1.68, 2.16) | 2.02 (1.96, 2.08) |
| Cervix Uteri | 0.24 (0.21, 0.27) | 0.22 (0.17, 0.32) | 0.30 (0.28, 0.32) |
| Corpus and Uterus, NOS | 0.51 (0.47, 0.55) | 0.41 (0.32, 0.55) | 0.61 (0.58, 0.64) |
| Ovary | 0.68 (0.64, 0.73) | 0.74 (0.63, 0.90) | 0.75 (0.71, 0.78) |
| Urinary Bladder | 0.25 (0.21, 0.29) | 0.24 (0.15, 0.39) | 0.28 (0.26, 0.31) |
| Kidney and Renal Pelvis | 0.21 (0.18, 0.24) | 0.43 (0.33, 0.59) | 0.38 (0.35, 0.41) |
| Brain and Other Nervous System | 0.29 (0.26, 0.33) | 0.25 (0.18, 0.38) | 0.36 (0.34, 0.39) |
| Thyroid | 0.14 (0.11, 0.17) | 0.07 (0.02, 0.19) | 0.12 (0.11, 0.14) |
| Hodgkin Lymphoma | 0.02 (0.01, 0.03) | 0.04 (0.01, 0.13) | 0.05 (0.04, 0.06) |
| Non-Hodgkin Lymphoma | 0.59 (0.54, 0.64) | 0.41 (0.32, 0.56) | 0.65 (0.62, 0.69) |
| Myeloma | 0.25 (0.22, 0.28) | 0.34 (0.25, 0.47) | 0.37 (0.34, 0.39) |
| Leukemia | 0.48 (0.43, 0.53) | 0.32 (0.24, 0.46) | 0.57 (0.54, 0.60) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.06) | 0.04 (0.02, 0.13) | 0.07 (0.06, 0.08) |
| Chronic Lymphocytic Leukemia | 0.03 (0.02, 0.05) | 0.02 (0.01, 0.12) | 0.07 (0.06, 0.08) |
| Acute Myeloid Leukemia | 0.25 (0.22, 0.29) | 0.16 (0.10, 0.27) | 0.23 (0.21, 0.25) |
| Chronic Myeloid Leukemia | 0.02 (0.01, 0.04) | 0.01 (0.00, 0.10) | 0.03 (0.02, 0.03) |

Devcan Version 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. A percent or confidence interval value of 0.00 represents a value that is below 0.005.